Your prediction
Pros and Cons of M1 Ltd. in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of M1 Ltd. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| M1 Ltd. | - | - | - | - | - | - | - |
| Spok Holdings Inc. | -0.510% | 3.125% | 8.791% | -36.129% | -9.836% | -23.256% | 50.000% |
| Apt Satellite Hldgs | 0.000% | 0.000% | 0.000% | -8.654% | -24.000% | -25.197% | -19.492% |
| SmarTone Telecommunications Holdings Ltd | -0.950% | -1.869% | 0.962% | 2.941% | 6.275% | -1.869% | 11.702% |
News
Contineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider Potential
Key Points
- Interested in Contineum Therapeutics, Inc.? Here are five stocks we like better.
- Contineum remains focused on PIPE-791 for idiopathic pulmonary fibrosis (IPF), saying the drug’s
IRSA Inversiones Y Representaciones Q3 Earnings Call Highlights
IRSA Inversiones Y Representaciones (NYSE:IRS) reported a sharply higher net result for the first nine months of fiscal 2026, supported by stronger performance across its rental businesses and